These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 20448288)

  • 1. Current evidence for the management of rheumatoid arthritis with glucocorticoids: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis.
    Gorter SL; Bijlsma JW; Cutolo M; Gomez-Reino J; Kouloumas M; Smolen JS; Landewé R
    Ann Rheum Dis; 2010 Jun; 69(6):1010-4. PubMed ID: 20448288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis.
    Gaujoux-Viala C; Nam J; Ramiro S; Landewé R; Buch MH; Smolen JS; Gossec L
    Ann Rheum Dis; 2014 Mar; 73(3):510-5. PubMed ID: 24395555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of glucocorticoids, conventional and targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis.
    Chatzidionysiou K; Emamikia S; Nam J; Ramiro S; Smolen J; van der Heijde D; Dougados M; Bijlsma J; Burmester G; Scholte M; van Vollenhoven R; Landewé R
    Ann Rheum Dis; 2017 Jun; 76(6):1102-1107. PubMed ID: 28356243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis.
    Nam JL; Ramiro S; Gaujoux-Viala C; Takase K; Leon-Garcia M; Emery P; Gossec L; Landewe R; Smolen JS; Buch MH
    Ann Rheum Dis; 2014 Mar; 73(3):516-28. PubMed ID: 24399231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glucocorticoids in rheumatoid arthritis: current status and future studies.
    Hua C; Buttgereit F; Combe B
    RMD Open; 2020 Jan; 6(1):. PubMed ID: 31958273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The supplementary therapeutic DMARD role of low-dose glucocorticoids in rheumatoid arthritis.
    Cutolo M; Spies CM; Buttgereit F; Paolino S; Pizzorni C
    Arthritis Res Ther; 2014 Nov; 16 Suppl 2(Suppl 2):S1. PubMed ID: 25608624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis.
    Gaujoux-Viala C; Smolen JS; Landewé R; Dougados M; Kvien TK; Mola EM; Scholte-Voshaar M; van Riel P; Gossec L
    Ann Rheum Dis; 2010 Jun; 69(6):1004-9. PubMed ID: 20447954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Remission in rheumatoid arthritis: wishful thinking or clinical reality?
    Sesin CA; Bingham CO
    Semin Arthritis Rheum; 2005 Dec; 35(3):185-96. PubMed ID: 16325659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update.
    Smolen JS; Landewé RBM; Bijlsma JWJ; Burmester GR; Dougados M; Kerschbaumer A; McInnes IB; Sepriano A; van Vollenhoven RF; de Wit M; Aletaha D; Aringer M; Askling J; Balsa A; Boers M; den Broeder AA; Buch MH; Buttgereit F; Caporali R; Cardiel MH; De Cock D; Codreanu C; Cutolo M; Edwards CJ; van Eijk-Hustings Y; Emery P; Finckh A; Gossec L; Gottenberg JE; Hetland ML; Huizinga TWJ; Koloumas M; Li Z; Mariette X; Müller-Ladner U; Mysler EF; da Silva JAP; Poór G; Pope JE; Rubbert-Roth A; Ruyssen-Witrand A; Saag KG; Strangfeld A; Takeuchi T; Voshaar M; Westhovens R; van der Heijde D
    Ann Rheum Dis; 2020 Jun; 79(6):685-699. PubMed ID: 31969328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glucocorticoid use in rheumatoid arthritis patients and the onset of pneumonia: a systematic review and meta-analysis.
    Elsouri KN; Arboleda V; Basbous L; Heiser S; Collins DP; Ragusa P; Baxter C; Cabrera D; Akhand T; Stermer E; Sharma K; Seguro C; Hardigan P; Kesselman M; Beckler MD
    J Osteopath Med; 2023 Apr; 123(4):179-186. PubMed ID: 36691851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current evidence for a strategic approach to the management of rheumatoid arthritis with disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis.
    Knevel R; Schoels M; Huizinga TW; Aletaha D; Burmester GR; Combe B; Landewé RB; Smolen JS; Sokka T; van der Heijde DM
    Ann Rheum Dis; 2010 Jun; 69(6):987-94. PubMed ID: 20448280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs.
    Smolen JS; Landewé R; Breedveld FC; Dougados M; Emery P; Gaujoux-Viala C; Gorter S; Knevel R; Nam J; Schoels M; Aletaha D; Buch M; Gossec L; Huizinga T; Bijlsma JW; Burmester G; Combe B; Cutolo M; Gabay C; Gomez-Reino J; Kouloumas M; Kvien TK; Martin-Mola E; McInnes I; Pavelka K; van Riel P; Scholte M; Scott DL; Sokka T; Valesini G; van Vollenhoven R; Winthrop KL; Wong J; Zink A; van der Heijde D
    Ann Rheum Dis; 2010 Jun; 69(6):964-75. PubMed ID: 20444750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis.
    Nam JL; Takase-Minegishi K; Ramiro S; Chatzidionysiou K; Smolen JS; van der Heijde D; Bijlsma JW; Burmester GR; Dougados M; Scholte-Voshaar M; van Vollenhoven R; Landewé R
    Ann Rheum Dis; 2017 Jun; 76(6):1113-1136. PubMed ID: 28283512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update.
    Smolen JS; Landewé R; Breedveld FC; Buch M; Burmester G; Dougados M; Emery P; Gaujoux-Viala C; Gossec L; Nam J; Ramiro S; Winthrop K; de Wit M; Aletaha D; Betteridge N; Bijlsma JW; Boers M; Buttgereit F; Combe B; Cutolo M; Damjanov N; Hazes JM; Kouloumas M; Kvien TK; Mariette X; Pavelka K; van Riel PL; Rubbert-Roth A; Scholte-Voshaar M; Scott DL; Sokka-Isler T; Wong JB; van der Heijde D
    Ann Rheum Dis; 2014 Mar; 73(3):492-509. PubMed ID: 24161836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The "dirty little secret" exposed in the 2013 EULAR recommendations for rheumatoid arthritis therapy.
    Kissin EY
    Clin Ther; 2014 Jul; 36(7):1114-6. PubMed ID: 24996488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EULAR definition of difficult-to-treat rheumatoid arthritis.
    Nagy G; Roodenrijs NMT; Welsing PM; Kedves M; Hamar A; van der Goes MC; Kent A; Bakkers M; Blaas E; Senolt L; Szekanecz Z; Choy E; Dougados M; Jacobs JW; Geenen R; Bijlsma HW; Zink A; Aletaha D; Schoneveld L; van Riel P; Gutermann L; Prior Y; Nikiphorou E; Ferraccioli G; Schett G; Hyrich KL; Mueller-Ladner U; Buch MH; McInnes IB; van der Heijde D; van Laar JM
    Ann Rheum Dis; 2021 Jan; 80(1):31-35. PubMed ID: 33004335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy, duration of use and safety of glucocorticoids: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis.
    Bergstra SA; Sepriano A; Kerschbaumer A; van der Heijde D; Caporali R; Edwards CJ; Verschueren P; de Souza S; Pope JE; Takeuchi T; Hyrich KL; Winthrop KL; Aletaha D; Stamm TA; Schoones JW; Smolen JS; Landewé RBM
    Ann Rheum Dis; 2023 Jan; 82(1):81-94. PubMed ID: 36410794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucocorticoids in rheumatoid arthritis: the silent companion in the therapeutic strategy.
    Berardicurti O; Ruscitti P; Pavlych V; Conforti A; Giacomelli R; Cipriani P
    Expert Rev Clin Pharmacol; 2020 Jun; 13(6):593-604. PubMed ID: 32434398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. When and for how long should glucocorticoids be used in rheumatoid arthritis? International guidelines and recommendations.
    Gaujoux-Viala C; Gossec L
    Ann N Y Acad Sci; 2014 May; 1318():32-40. PubMed ID: 24827544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Similar effects of disease-modifying antirheumatic drugs, glucocorticoids, and biologic agents on radiographic progression in rheumatoid arthritis: meta-analysis of 70 randomized placebo-controlled or drug-controlled studies, including 112 comparisons.
    Graudal N; Jürgens G
    Arthritis Rheum; 2010 Oct; 62(10):2852-63. PubMed ID: 20560138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.